Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 11:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 1,263 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Copd Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety Trial of 12 Weeks of Treatment With Nebulized SUN-101 in Patients With COPD

NCT02347761
View directory record Official record
Conditions
COPD
Interventions
SUN-101 50 mcg BID eFlow (CS) nebulizer, SUN-101 25 mcg BID eFlow (CS) nebulizer, Placebo BID eFlow Closed System (CS) nebulizer
Drug
Lead sponsor
Sunovion Respiratory Development Inc.
Industry
Eligibility
40 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
44
States / cities
Anniston, Alabama • Phoenix, Arizona • Tempe, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

12 / 48 Week Pivotal PFT vs PBO in COPD I

NCT00782210
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Olodaterol (BI1744), placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
625 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
21
States / cities
Jasper, Alabama • Berkeley, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Phase 4 Interventional Results available

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.

NCT00359788
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Combivent (Ipratropium/Albuterol)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.

NCT00528996
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
BEA 2180 BR, Tiotropium Bromide, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 100 Years
Enrollment
2,080 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
56
States / cities
Jasper, Alabama • Mobile, Alabama • Berkeley, California + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2021 · Synced Oct 22, 2026, 11:56 PM EDT
Terminated No phase listed Observational

Impact of Inhaled Treprostinil Sodium on Ventilation Perfusion Matching

NCT01494896
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Jacksonville, Florida • Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Not applicable Interventional Results available

Flunisolide HFA in Children With Small Airway Disease

NCT02404103
View directory record Official record
Conditions
Childhood Asthma
Interventions
Flunisolide HFA
Drug
Lead sponsor
University of Louisville
Other
Eligibility
6 Years to 18 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease

NCT02573870
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Batefenterol + Fluticasone Furoate, Placebo, Albuterol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Phoenix, Arizona • Hollywood, Florida • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 22, 2026, 11:56 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

NCT02393807
View directory record Official record
Conditions
Healthy
Interventions
PF 06260414 solid dose formulation, PF-06260414 nanosuspension
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Phase 3 Interventional

A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD

NCT00206167
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Budesonide/formoterol pMDI, Formoterol Turbuhaler
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
131
States / cities
Birmingham, Alabama • Huntsville, Alabama • Jasper, Alabama + 128 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2009 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chronic Obstructive Pulmonary Disorder and Acute Exercise

NCT02780219
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
stable amino acid infusion, acute exercise with amino acid infusion, 24-hour post exercise amino acid infusion
Other
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease

NCT02216630
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Adipose Derived Stem Cell (ADSC) Therapy
Drug
Lead sponsor
Kimera Society Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Davie, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Not applicable Interventional Results available

Differentiating the Effects of Substance P and Beta-endorphin

NCT01854177
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Aprepitant, Placebo
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Oct 30, 2018 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Not applicable Interventional

Cognitive Behavioral Therapy for COPD

NCT01694628
View directory record Official record
Conditions
COPD, Depression
Interventions
CLIMB (COPD Lifestyle, Mood, and Behavior)
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
40 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 5, 2021 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breathe Easier II: A Dyad-based Multiple Behavior Intervention

NCT05956782
View directory record Official record
Conditions
Lung Cancer, Nonsmall Cell, COPD, Self-Management, Physical Inactivity, Stress, Quality of Life
Interventions
Breathe Easier
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT02164513
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
10,355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
269
States / cities
Athens, Alabama • Birmingham, Alabama • Florence, Alabama + 226 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 22, 2026, 11:56 PM EDT
Recruiting Not applicable Interventional

Inclined Versus Standard Exercise for COPD Patients

NCT06749262
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
walking on incline or walking at increasing speed for 36 visits
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 22, 2026, 11:56 PM EDT
Not listed No phase listed Observational

Outcomes Data of Adipose Stem Cells to Treat Chronic Obstructive Pulmonary Disease

NCT02348060
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
StemGenex
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2018 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Phase 1 Interventional Results available

A Study to Assess the PK and Safety of PT010 in Subjects With COPD Following Single and Repeat Dose

NCT03250182
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT010
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Not applicable Interventional

Social Incentives to Increase Mobility

NCT03321279
View directory record Official record
Conditions
Pneumonia, Diabetes, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Interventions
Social Incentive
Behavioral
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetic, Safety and Tolerability Study of Aclidinium/Formoterol Fixed Dose Combination and Formoterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01551888
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Aclidinium/formoterol 400/12μg, Formoterol
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Spartanburg, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 14, 2017 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Early Phase 1 Interventional Results available

The Effects of Tiotropium on the Cough Reflex in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT00870896
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Chronic Bronchitis
Interventions
Tiotropium
Drug
Lead sponsor
ThomasTruncale
Other
Eligibility
40 Years to 80 Years · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2014 · Synced Oct 22, 2026, 11:56 PM EDT
Completed No phase listed Observational

Evaluating Genetic Factors That May Contribute to Elastin Function and the Development of Chronic Obstructive Pulmonary Disease

NCT00725309
View directory record Official record
Conditions
Emphysema, Pulmonary Disease, Chronic Obstructive
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Phase 3 Interventional Results available

Effect on Exercise Endurance and Lung Hyperinflation of Tiotropium + Olodaterol in COPD Patients.

NCT01533935
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, tiotropium + Olodaterol, Tiotropium, Olodaterol, Respimat
Drug · Device
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years to 75 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
11
States / cities
Phoenix, Arizona • Austell, Georgia • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2015 · Synced Oct 22, 2026, 11:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Supplemental Oxygen on Maximal Oxygen Consumption in Patients With Chronic Obstructive Pulmonary Disease

NCT01294033
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Fractional inspired oxygen (FiO2) 0.21, Fractional inspired oxygen 0.28
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Oct 22, 2026, 11:56 PM EDT